This established forum is the key industry-led networking forum to gain clear insights into the latest discovery, translational and manufacturing advancements, and how to address associated development challenges encountered within this therapeutic modality.

If your research teams are looking to tackle major challenges in bispecific drug functionality, including tumor-specific antigen targeting, binding affinity or multi-specific antibody formats, this elite conference presents an insight that can influence the design and development of your product. Whether it is a CD3-engaging T-cell re-directing BsAbs targeting checkpoint inhibitors or a tumor-associated antigen, this is the key industry meeting you should be attending.

Alongside clinical development questions, this definitive forum will provide direction on the developability of BsAbs platforms, with dedicated sessions on product design and expression, and scale-up of the manufacturing process.

Join the 13^th World Bispecific Summit in person for the first time in over 2 years to connect with chemistry, discovery, and clinical drug hunters with expertise in protein engineering, clinical pharmacodynamic, prognostic biomarkers, process development and manufacturability.